Replies to post #73502 on ALERTS, CHARTS, & HOT STOCKS

[read_this_n0w]

The University of British Columbia Studies the Development of ProtoKinetix` AAGP Anti-Inflammatory for the$20-Billion Eye Treatment Market <PKTX.OB><PKTXE.OB

VANCOUVER, British Columbia--(Business Wire)--
ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com), a biotechnology company that
has developed and patented a family of synthetic anti-aging glycopeptides (AAGP)
for medicine, biotechnology and cosmetic industries, has selected the University
of British Columbia to study the ability of AAGP to suppress eye inflammation.

ProtoKinetix` management believes that these studies will lead to the
development of an effective non-steroidal anti-inflammation treatment. This
multi-billion dollar market is just the first of the many applications that
ProtoKinetix intends to exploit as a platform for therapeutics targeting
specific diseases. Inflammation is the cause of destruction of otherwise healthy
tissues and organs.

Inflammation of the eye has many causes including viruses, bacteria and
auto-immune diseases such as rheumatoid arthritis. If left untreated, the
inflammation can lead to glaucoma, cataracts and total loss of vision. Current
treatments include the frequent and constant use of topical corticosteroids that
have potentially serious health issues.

Upon proving up this low risk and powerful anti-inflammation agent, ProtoKinetix
believes that AAGP will become the therapy of choice for inflammatory eye
disease.

About ProtoKinetix

ProtoKinetix, Inc. is a biotechnology company that has developed and patented a
family of synthetic anti-aging glycopeptides (AAGP) for medicine and the
biotechnology and cosmetic industries. PKTX`s primary focus is on the
therapeutic potential for AAGP in the treatment of Diabetes, inflammatory
diseases, skin protection and anti-aging.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor"
for forward-looking statements. Some information included in this press release
contains statements that are forward-looking. Such forward-looking information
involves significant risks and uncertainties that could affect anticipated
results in the future and, accordingly, these results may differ materially from
those expressed in any forward-looking statements made by or on behalf of the
Company. For a description of additional risks and uncertainties, please refer
to the Company`s filings with the Securities and Exchange Commission.

Ross L. Senior -President and CEO

ProtoKinetix, Inc.
Blair Henderson
604-926-6627

Copyright Business Wire 2011